Eric Palmer

Biography for Eric Palmer

Eric Palmer, Senior Editor

Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family. Eric is based in Kansas City and can be reached at epalmer@fiercemarkets.com.

Articles by Eric Palmer

Adcock shareholder on defense for opposing buyout by CFR

The largest shareholder for South Africa's Adcock Ingram is defending its opposition to the drugmaker being bought by CFR after Abbott bought Chile-based CFR for $3 billion.

Indian drugmakers giving up 'advantage' to move to higher-margin drugs

The "Indian advantage" has been the ability to do clinical trials and manufacture drugs for global export at perhaps a tenth of the cost that drugmakers in the West face. But with actions by the FDA and Western regulators forcing plants from exporting to those markets and a need to move to higher-margin drugs, some Indian drugmakers are giving up that edge in an effort to raise profits.

EU agents seize more than €10M worth of counterfeit drugs, arrest 12

Authorities from 8 European Union countries, backed by Europol and Eurojust, have arrested a dozen suspects and seized more than €10 million worth of counterfeit drugs, mostly fakes of erectile dysfunction drugs that an organized crime group was selling online. The raid, announced Monday, came after an investigation that lasted nearly two years.

Wockhardt again recalls generic of AstraZeneca drug after it fails testing

India's troubled Wockhardt is again expanding its voluntary recall of metoprolol succinate extended-release tablets, a generic of AstraZeneca's hypertension drug Toprol XR. This is Wockhardt's third recall of the drug in about four months.

Boehringer Ingelheim recalls cancer drug made at ill-fated Bedford plant

Boehringer Ingelheim is still recalling products that were made at its Ben Venue plant in Bedford, OH, even though it no longer owns the massive site.

Sources: West Pharmaceutical looks at $130M investment in Ireland

Pennsylvania-based West Pharmaceutical is again looking east for expansion. The maker of glass products for the pharma biz, which recently opened a plant in India, is now looking at adding a facility in Ireland that could run to €100 million.

UPDATED: GSK, NewLink ramp up production of Ebola drugs, even as they conduct trials

In an effort to contain the Ebola outbreak in Africa that has already killed more than 1,500 people, companies around the world, including GlaxoSmithKline, are fast-tracking treatments and vaccines to try to get ahead of the disease spread. And in an effort to do that, companies are manufacturing doses, even as they are testing drugs, so that they will have product ready to go ASAP.

Grand River opens new finishing facility

Grand River Aseptic Manufacturing (GRAM), a small parenteral contract manufacturing company in Grand Rapids, MI, has opened a new 28,000-square-foot facility for its finishing operations, inspection services and storage, as well as housing a substantially larger lab, Contract Pharma reports.

Merck KGaA starts work on what will be its second-largest plant

Merck KGaA emphasized the importance of China as a market when it announced last year it would build a new plant there, and again last month when it announced it was getting ready to start construction on the facility. And this week, just in case anyone had missed it, the drugmaker said construction had begun on the plant which will make meds on China's essential drug list.

NAFTA says FDA was in its rights to ban Apotex plants

It's tough luck for Canada's Apotex in its international slug fest with the FDA. An arbitration panel has tossed its claim that the FDA violated the North American Free Trade Act when it banned products from its plants in Toronto and Quebec from 2009 to 2011.